It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Accumulating evidence has demonstrated the essential role of long noncoding RNAs (lncRNAs) in various types of human cancer, including pancreatic cancer (PC). However, the functions and regulatory mechanisms of nuclear receptor subfamily 2 group F member 1 antisense RNA 1 (NR2F1-AS1) that are responsible for its role in the malignant progression of PC cells remains to be investigated. In this study, the biological effects of NR2F1-AS1 and NR2F1 in PC were investigated by in vitro and in vivo experiments. The mechanisms of NR2F1-AS1 were monitored by bioinformatic predictive analysis and confirmatory experiments. Our results indicated that NR2F1-AS1 was overexpressed and positively correlated with poor survival in PC. Depletion of NR2F1-AS1 restrained PC cell proliferation, migration, invasion, and suppressed xenograft tumor growth and metastasis in vitro and in vivo. Mechanistic experiments suggested that NR2F1-AS1 positively regulated the neighboring NR2F1 gene, which subsequently activated AKT/mTOR signaling, resulting in the upregulation of hypoxia-inducible factor-1α (HIF-1α). Further investigations elucidated that NR2F1-AS1 expression was transcriptionally regulated by HIF-1α under hypoxia. These findings demonstrated that hypoxia-induced NR2F1-AS1 expression directly increased NR2F1 levels to promote PC cell proliferation, migration, and invasion by activating AKT/mTOR signaling. Together, these findings suggest that NR2F1-AS1 could be a prospective therapeutic target for PC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Guizhou Medical University, College of Basic Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891); The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China (GRID:grid.443382.a) (ISNI:0000 0004 1804 268X); Guizhou Medical University, Department of Translational Medicine, College of Clinical Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891)
2 Guizhou Medical University, College of Basic Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891); Guizhou Medical University, Department of Translational Medicine, College of Clinical Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891); The Affiliated Hospital of Guizhou Medical University, Department of Hepatic-Biliary-Pancreatic Surgery, Guiyang, China (GRID:grid.452244.1)
3 The Affiliated Hospital of Guizhou Medical University, Department of Hepatic-Biliary-Pancreatic Surgery, Guiyang, China (GRID:grid.452244.1); Guizhou Medical University, College of Clinical Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891)
4 The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China (GRID:grid.443382.a) (ISNI:0000 0004 1804 268X)
5 Guizhou Medical University, College of Basic Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891); The Affiliated Hospital of Guizhou Medical University, Department of Hepatic-Biliary-Pancreatic Surgery, Guiyang, China (GRID:grid.452244.1); Guizhou Medical University, College of Clinical Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891)
6 Guizhou Medical University, College of Basic Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891); Guizhou Medical University, Department of Translational Medicine, College of Clinical Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891); The Affiliated Hospital of Guizhou Medical University, Department of Hepatic-Biliary-Pancreatic Surgery, Guiyang, China (GRID:grid.452244.1); Guizhou Medical University, College of Clinical Medicine, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891)